Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran
BACKGROUND: Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. METHOD: We used the baseline data of the Pars cohort study (...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536013/ https://www.ncbi.nlm.nih.gov/pubmed/36203125 http://dx.doi.org/10.1186/s12872-022-02872-7 |
_version_ | 1784802899961839616 |
---|---|
author | Mohsenzadeh, Pooran Ardekani, Ali Poustchi, Hossein Mohammadi, Zahra Abdipour Mehrian, Seyed Reza Bazrafshan Drissi, Hamed Rahimian, Zahra Taherifard, Erfan Nabavizadeh, Ali kamalipour, Alireza Mesgarpour, Bita Malekzadeh, Fatemeh Molavi Vardanjani, Hossein |
author_facet | Mohsenzadeh, Pooran Ardekani, Ali Poustchi, Hossein Mohammadi, Zahra Abdipour Mehrian, Seyed Reza Bazrafshan Drissi, Hamed Rahimian, Zahra Taherifard, Erfan Nabavizadeh, Ali kamalipour, Alireza Mesgarpour, Bita Malekzadeh, Fatemeh Molavi Vardanjani, Hossein |
author_sort | Mohsenzadeh, Pooran |
collection | PubMed |
description | BACKGROUND: Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. METHOD: We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated. RESULTS: Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57–4.94), high socioeconomic status (PR: 1.65; 95% CI 1.07–2.54), tobacco-smoking (PR: 1.35; 95% CI 1.00–1.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30–1.53), high physical activity (PR: 0.66; 95% CI 0.45–0.95), use of opiate ever (PR: 0.46; 95% CI 0.26–0.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12–0.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60 years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs. CONCLUSION: Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial. |
format | Online Article Text |
id | pubmed-9536013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95360132022-10-07 Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran Mohsenzadeh, Pooran Ardekani, Ali Poustchi, Hossein Mohammadi, Zahra Abdipour Mehrian, Seyed Reza Bazrafshan Drissi, Hamed Rahimian, Zahra Taherifard, Erfan Nabavizadeh, Ali kamalipour, Alireza Mesgarpour, Bita Malekzadeh, Fatemeh Molavi Vardanjani, Hossein BMC Cardiovasc Disord Research BACKGROUND: Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. METHOD: We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated. RESULTS: Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57–4.94), high socioeconomic status (PR: 1.65; 95% CI 1.07–2.54), tobacco-smoking (PR: 1.35; 95% CI 1.00–1.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30–1.53), high physical activity (PR: 0.66; 95% CI 0.45–0.95), use of opiate ever (PR: 0.46; 95% CI 0.26–0.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12–0.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60 years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs. CONCLUSION: Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial. BioMed Central 2022-10-06 /pmc/articles/PMC9536013/ /pubmed/36203125 http://dx.doi.org/10.1186/s12872-022-02872-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mohsenzadeh, Pooran Ardekani, Ali Poustchi, Hossein Mohammadi, Zahra Abdipour Mehrian, Seyed Reza Bazrafshan Drissi, Hamed Rahimian, Zahra Taherifard, Erfan Nabavizadeh, Ali kamalipour, Alireza Mesgarpour, Bita Malekzadeh, Fatemeh Molavi Vardanjani, Hossein Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title | Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title_full | Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title_fullStr | Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title_full_unstemmed | Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title_short | Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran |
title_sort | population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the pars cohort study from iran |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536013/ https://www.ncbi.nlm.nih.gov/pubmed/36203125 http://dx.doi.org/10.1186/s12872-022-02872-7 |
work_keys_str_mv | AT mohsenzadehpooran populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT ardekaniali populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT poustchihossein populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT mohammadizahra populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT abdipourmehrianseyedreza populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT bazrafshandrissihamed populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT rahimianzahra populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT taherifarderfan populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT nabavizadehali populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT kamalipouralireza populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT mesgarpourbita populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT malekzadehfatemeh populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran AT molavivardanjanihossein populationbasedpatternofmedicationuseandprevalenceofpolypharmacyamongpatientswithcardiovasculardiseasesresultsoftheparscohortstudyfromiran |